Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib in Progressive Advanced Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors
NCT01525550Phase 4Completed
- Sponsor
- Pfizer
- Start
- Jun 2012
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 15
01
Overview
A Phase 4 trial of sunitinib in Pancreatic neuroendocrine tumor (PanNET), sponsored by Pfizer. Started Jun 2012; status: completed.
02
Drugs
sunitinib
03
Conditions
Pancreatic neuroendocrine tumor (PanNET)
Beyond the preview
Go deeper on NCT01525550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01525550.